Inhaled treprostinil shows promise in interstitial lung disease associated with pulmonary hypertension

Treatment with inhaled treprostinil was associated with significant improvements in exercise capacity in patients with pulmonary hypertension and interstitial lung disease (ILD), according to results from a Phase III trial present at a virtual session at American Thoracic Society 2020.

In the multicenter, randomized INCREASE trial, 326 patients with ILD with pulmonary hypertension were randomized to receive treprostinil or placebo for 16 weeks. Patients treated with treprostinil experienced increases in 6-minute walking distance of 21 meters after 16 weeks compared with patients treated with placebo.

Approximately 23% of patients treated with treprostinil and 33% with placebo worsened during the trial.

Adverse events included cough, headache, dyspnea, dizziness, and nausea.

View the presentation here. 

Reference
Nathan SD, et al. Inhaled Treprostinil in Interstitial Lung Disease Associated Pulmonary Hypertension: The INCREASE Study. Presented at the American Thoracic Society (ATS) on June 24, 2020.